20 March 2026 in SSRN Electronic Journal
BackgroundTumor treating fields (TTFields) improve survival in glioblastoma (GBM), but their clinical efficacy is limited by inefficient electric-field delivery through the high-impedance scalp and skull. This attenuation reduces intratumoral electric field, increases superficial heating, and contributes to treatment-related dermatologic toxicity.MethodsWe propose an intracranial-implanted coupled-electrode TTFields strategy (ICE-TTF), in which a single depth electrode implanted in the tumor cavity is coupled with distributed extracranial counter-electrodes. Finite-element modeling was used to optimize electrode geometry and evaluate electric-field and thermal distributions. A segmented intracranial electrode was examined for directional field switching. Therapeutic efficacy was assessed in rat glioma models using bioluminescence imaging and histology. Impedance monitoring and electrochemical assays were performed to evaluate interface behavior and electrode safety.ResultsICE-TTF generated therapeutically relevant tumor electric fields with substantially lower power and minimal temperature rise compared with external TTFields. Segmented contacts enabled switching between predominantly radial and tangential field components. In vivo, ICE-TTF suppressed tumor growth and reduced proliferative activity. Electrode–tissue impedance correlated with tumor progression, supporting its potential as a monitoring biomarker. Electrochemical modeling, ion-release measurements, and histology confirmed the stability and biocompatibility of PtIr electrodes under high-frequency stimulation.ConclusionsICE-TTF introduces an intracranial–extracranial coupled electrode architecture that improves TTFields energy delivery efficiency using a single implanted electrode while enabling directional field modulation and impedance-based monitoring. This strategy may provide a minimally invasive and energy-efficient platform for adaptive electric-field therapy in glioblastoma.
17 June 2026 in Brain Stimulation
Tumor treating fields (TTFields) improve survival in glioblastoma (GBM), but their clinical efficacy is limited by inefficient electric-field delivery through the high-impedance scalp and skull. This attenuation reduces intratumoral electric-field intensity and increases superficial power deposition, while external arrays remain associated with skin-interface complications. We propose an intracranial-implanted coupled-electrode TTFields strategy (ICE-TTF), in which a single depth electrode implanted in the tumor cavity is coupled with distributed extracranial counter-electrodes. Finite-element modeling was used to optimize electrode geometry and evaluate electric-field and thermal distributions. A segmented intracranial electrode was examined for directional field switching. Short-term anti-tumor activity was assessed in rat glioma models using bioluminescence imaging and histology. Impedance monitoring and electrochemical assays were performed to evaluate interface behavior, short-term electrode stability, and tissue response. In simulations, ICE-TTF generated tumor electric-field intensities within the TTFields-relevant range with substantially lower power and lower temperature rise than external TTFields under matched coverage assumptions. Segmented contacts enabled switching between predominantly radial and tangential field components. In vivo, ICE-TTF attenuated the BLI-derived tumor-burden signal and reduced proliferative activity. Electrode-tissue impedance was associated with BLI-derived tumor-burden progression, supporting its potential as a candidate monitoring signal. Electrochemical modeling, ion-release measurements, and short-term histology supported short-term electrochemical stability and peri-electrode tissue compatibility of Pt-Ir electrodes under the tested high-frequency stimulation conditions. ICE-TTF represents a candidate reduced-implant-burden intracranial TTFields delivery architecture. The current data support simulation-based field-delivery feasibility, short-term proof-of-concept anti-tumor activity, and future impedance-informed monitoring, while direct comparative efficacy, survival benefit, and closed-loop control remain to be validated.